NO20060093L - Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav - Google Patents

Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav

Info

Publication number
NO20060093L
NO20060093L NO20060093A NO20060093A NO20060093L NO 20060093 L NO20060093 L NO 20060093L NO 20060093 A NO20060093 A NO 20060093A NO 20060093 A NO20060093 A NO 20060093A NO 20060093 L NO20060093 L NO 20060093L
Authority
NO
Norway
Prior art keywords
methods
glycoprotein
plate
fusion polypeptides
variant fusion
Prior art date
Application number
NO20060093A
Other languages
English (en)
Norwegian (no)
Inventor
Gray D Shaw
Ravindra Kumar
Dianne S Sako
Jin Xu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20060093L publication Critical patent/NO20060093L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
NO20060093A 2003-06-11 2006-01-06 Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav NO20060093L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47752503P 2003-06-11 2003-06-11
PCT/US2004/019057 WO2004111089A2 (fr) 2003-06-11 2004-06-14 Polypeptides de fusion de variants de glycoproteines ib-$g(a) de plaquette et leurs methodes

Publications (1)

Publication Number Publication Date
NO20060093L true NO20060093L (no) 2006-03-01

Family

ID=33551724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060093A NO20060093L (no) 2003-06-11 2006-01-06 Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav

Country Status (16)

Country Link
US (2) US7727535B2 (fr)
EP (2) EP2522677A1 (fr)
JP (1) JP2007537710A (fr)
KR (1) KR20060022261A (fr)
CN (1) CN100436480C (fr)
AU (1) AU2004247737B2 (fr)
BR (1) BRPI0411289A (fr)
CA (1) CA2530972A1 (fr)
HK (1) HK1095152A1 (fr)
IL (2) IL172337A (fr)
MX (1) MXPA05013509A (fr)
NO (1) NO20060093L (fr)
NZ (1) NZ544165A (fr)
RU (1) RU2403262C2 (fr)
WO (1) WO2004111089A2 (fr)
ZA (1) ZA200510331B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
DE102007031708A1 (de) * 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
EP2193373A4 (fr) 2007-08-23 2010-07-28 Bloodct Of Wisconsin Inc Procédés et kits pour mesurer le facteur von willebrand
LT2750690T (lt) * 2011-11-15 2019-01-10 The Walter And Eliza Hall Institute Of Medical Research Tirpus mediatorius
WO2013096932A1 (fr) * 2011-12-23 2013-06-27 Vasculogics, Inc. Compositions et procédés pour le traitement de thrombose et la prolongation de la survie de plaquettes stockées
ES2614352T3 (es) 2014-03-11 2017-05-30 Siemens Healthcare Diagnostics Products Gmbh Método para la detección de moduladores de la interacción de GPIb-trombina
WO2015168474A1 (fr) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Protéines de fusion pour le traitement du cancer et procédés associés
JP2017520575A (ja) 2014-07-01 2017-07-27 ファイザー・インク 二重特異的ヘテロ二量体ダイアボディおよびその使用
EP4386387A2 (fr) 2018-02-20 2024-06-19 F. Hoffmann-La Roche AG Composition comprenant une protéine recombinante du récepteur gpiba
CN113264995A (zh) * 2021-05-26 2021-08-17 苏州大学 一种血小板GPIbα蛋白相关的抗原表位肽及其应用
WO2023007182A1 (fr) * 2021-07-29 2023-02-02 The University Of Birmingham Inhibiteurs d'interactions de protéines
WO2023109903A1 (fr) * 2021-12-15 2023-06-22 上海循曜生物科技有限公司 Produit et méthode de traitement de la thrombocytopénie

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88308A0 (en) * 1987-11-17 1989-06-30 Scripps Clinic Res Peptides that block the binding of von willebrand factor
US5340727A (en) 1987-11-17 1994-08-23 The Scripps Research Institute GPIbα fragments and recombinant DNA expression vectors
US4899195A (en) * 1988-01-29 1990-02-06 Ushio Denki Method of exposing a peripheral part of wafer
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5194743A (en) * 1990-04-06 1993-03-16 Nikon Corporation Device for positioning circular semiconductor wafers
JP2874280B2 (ja) * 1990-05-16 1999-03-24 株式会社ニコン 周縁露光装置及び周縁露光方法
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5317097A (en) 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
TW316322B (fr) * 1995-10-02 1997-09-21 Ushio Electric Inc
JP3237522B2 (ja) * 1996-02-05 2001-12-10 ウシオ電機株式会社 ウエハ周辺露光方法および装置
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
JP4380067B2 (ja) 1998-04-23 2009-12-09 味の素株式会社 抗血栓活性物質及びグリコカリシンの検出法
AR035779A1 (es) 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos

Also Published As

Publication number Publication date
US20110039780A1 (en) 2011-02-17
AU2004247737B2 (en) 2009-04-23
EP1636266A2 (fr) 2006-03-22
CA2530972A1 (fr) 2004-12-23
CN1823090A (zh) 2006-08-23
IL220272A0 (en) 2012-07-31
WO2004111089A2 (fr) 2004-12-23
AU2004247737A1 (en) 2004-12-23
RU2403262C2 (ru) 2010-11-10
JP2007537710A (ja) 2007-12-27
RU2006100306A (ru) 2006-06-10
EP2522677A1 (fr) 2012-11-14
KR20060022261A (ko) 2006-03-09
ZA200510331B (en) 2007-03-28
US20050089888A1 (en) 2005-04-28
WO2004111089A3 (fr) 2005-05-12
MXPA05013509A (es) 2006-04-05
US7727535B2 (en) 2010-06-01
BRPI0411289A (pt) 2006-08-01
HK1095152A1 (en) 2007-04-27
CN100436480C (zh) 2008-11-26
IL172337A (en) 2012-07-31
NZ544165A (en) 2008-12-24

Similar Documents

Publication Publication Date Title
NO20060093L (no) Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav
IL245462A0 (en) Antagonists of human origin against cmet
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
GB0700909D0 (en) Novel antigen-binding polypeptides and their uses
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
UA89734C2 (en) ANTAGONISTS of muscarinic acetylcholine receptors
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
NO20034056D0 (no) Proliferative sykdommer
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
CR9428A (es) Metodos para el tratamiento y la prevencion de fibrosis
DE602005026169D1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
DK1899334T3 (da) Naphthyridinforbindelser
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
DE60312211D1 (de) Haarbehandlungsmittel
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
UY28344A1 (es) Nuevos compuestos
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
WO2007034490A3 (fr) Peptides diastereomeriques destines a la modulation de l'immunite due aux lymphocytes t

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application